Abstract
BackgroundAndrogen deprivation therapy (ADT) is a mainstay therapy for prostate cancer, and a risk factor for bone mineral density (BMD) loss and fractures. Despite this risk, few patients undergo measurement...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
